AR074776A1 - Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente - Google Patents

Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente

Info

Publication number
AR074776A1
AR074776A1 ARP090104945A ARP090104945A AR074776A1 AR 074776 A1 AR074776 A1 AR 074776A1 AR P090104945 A ARP090104945 A AR P090104945A AR P090104945 A ARP090104945 A AR P090104945A AR 074776 A1 AR074776 A1 AR 074776A1
Authority
AR
Argentina
Prior art keywords
patient
cell
methyl
macular degeneration
formula
Prior art date
Application number
ARP090104945A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR074776A1 publication Critical patent/AR074776A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

En la presente memoria se proporcionan métodos para prevenir, tratar o aliviar una degeneración macular tal como degeneración macular seca, degeneración macular húmeda y degeneración macular asociada a la edad en un paciente. Reivindicación 1: Un método para prevenir, tratar o aliviar la neovascularización coroidal en un paciente, que comprende administrar al paciente una cantidad eficaz de un compuesto que modula el sistema inmunitario del paciente, en donde el sistema inmunitario tiene respuestas inmunes de tipo I y respuestas inmunes de tipo II, de tal modo que administrar el compuesto al paciente aumenta las respuestas inmunes de tipo I en el paciente comparado con las respuestas inmunes de tipo I en el paciente antes de la administración del compuesto. Reivindicación 2: El método de la reivindicación 1, en el que el compuesto se selecciona del grupo que consiste en: (a) un inhibidor de la multicinasa syk; (b) un inhibidor de hPGDS; y (c) un antagonista de DP. Reivindicación 3: El método de la reivindicación 2, en el que el inhibidor de la multicinasa syk se selecciona del grupo que consiste en éster mono-{6-[5-fluoro-2-(3,4,5-trimetoxi-fenilamino)-pirimidin-4-ilamino)-2,2-dimetil-3-oxo-2,3-dihidro-pirido[3,2-b][1,4]oxazin-4-ilmetílico} del ácido fosfórico, sal de ácido acético de fórmula (1) y 2-[4-(7-etil-5H-pirrolo[2,3-b]pirazin-6-il-fenil]-propan-2-ol de fórmula (2). Reivindicación 4: El método de la reivindicación 2, en el que el inhibidor de hPGDS se selecciona del grupo que consiste en: indol-1-ilamida del ácido 2-(3-fluoro-fenil)-4-metil-pirimidina-5-carboxílico de fórmula (3); 3-[5-(1-hidroxi-1-metil-etil)-1,2,4-oxadiazol-3-il]-bencilamida del ácido 2-piridin-2-il-pirimidina-5-carboxílico de fórmula (4); y (5-fluoro-3-metil-indol-1-il)amida del ácido 4-metil-2-piridin-2-il-pirimidina-5-carboxílico de fórmula (5). Reivindicación 5: El método de la reivindicación 2, en el que el antagonista de DP es ácido 2-(3-{6-[2-(2,4-dicloro-fenil)-etilamino]-2-metoxi-pirimidin-4-il}-fenil)-2-metil-propiónico, sal de ácido fosfórico de fórmula (6). Reivindicación 6: El método de cualquiera de las reivindicaciones 1-5, en el que el compuesto modula la actividad de un inmunocito en el paciente. Reivindicación 7: El método de la reivindicación 6, en el que el inmunocito es una célula asesina natural (célula NK), una célula T asesina natural (célula NKT), un mastocito, una célula dendrítica, un granulocito seleccionado del grupo que consiste en un eosinófilo, un basófilo y un neutrófilo, o cualquier combinación de los mismos.
ARP090104945A 2008-12-18 2009-12-17 Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente AR074776A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13870508P 2008-12-18 2008-12-18
FR0955794 2009-08-25

Publications (1)

Publication Number Publication Date
AR074776A1 true AR074776A1 (es) 2011-02-09

Family

ID=41716610

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104945A AR074776A1 (es) 2008-12-18 2009-12-17 Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente

Country Status (15)

Country Link
US (1) US20110301125A1 (es)
EP (2) EP2370077A2 (es)
JP (1) JP2012512895A (es)
KR (1) KR20110097955A (es)
CN (1) CN102316868A (es)
AR (1) AR074776A1 (es)
AU (1) AU2009335749A1 (es)
BR (1) BRPI0922465A2 (es)
CA (1) CA2747478A1 (es)
IL (1) IL213550A0 (es)
MX (1) MX2011006391A (es)
SG (2) SG196770A1 (es)
TW (1) TW201034675A (es)
UY (1) UY32346A (es)
WO (1) WO2010080563A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531699T1 (de) * 2007-06-29 2011-11-15 Sanofi Sa Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4-
CN102666508A (zh) 2009-10-08 2012-09-12 赛诺菲 作为***素d合酶抑制剂的苯基噁二唑衍生物
CN105126122A (zh) * 2014-12-12 2015-12-09 中国人民解放军第四军医大学 microRNA mimics用于制备治疗脉络膜新生血管药物的应用
CN107519491B (zh) * 2017-09-04 2020-08-25 无锡市人民医院 Copb2抑制剂的用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4879119A (en) 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2055280T3 (es) 1989-12-04 1994-08-16 Searle & Co Sistema monocapa para la administracion transdermica de farmacos.
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
EP0617665B1 (en) 1991-12-18 1999-03-31 Minnesota Mining And Manufacturing Company Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6977283B1 (en) 1998-04-07 2005-12-20 Exxonmobil Chemical Patents Inc. Polymerization process
EP0964361A1 (en) 1998-06-08 1999-12-15 International Business Machines Corporation Protection of sensitive information contained in integrated circuit cards
WO2001028473A1 (en) 1999-10-21 2001-04-26 Alcon Universal Ltd. Sub-tenon drug delivery
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
AU2002334217B2 (en) 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
WO2005051942A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Indazole compounds and methods of use thereof as protein kinase inhibitors
DOP2005000039A (es) 2004-03-26 2005-10-31 Aventis Pharma Inc Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
WO2005102303A2 (en) * 2004-04-21 2005-11-03 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1928456B1 (en) * 2005-09-30 2015-04-22 Miikana Therapeutics, Inc. Substituted pyrazole compounds
CN101316587B (zh) * 2005-09-30 2013-04-03 迈卡纳治疗股份有限公司 取代的吡唑化合物
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
AR060403A1 (es) * 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
BRPI0718162A2 (pt) * 2006-10-20 2013-11-26 Irm Llc Composição e métodos para modulara os receptores c-kit e pdgfr
US8163902B2 (en) * 2006-11-21 2012-04-24 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JP2011513488A (ja) 2008-03-10 2011-04-28 サノフィ−アベンティス 眼関連障害の治療
CN102209710A (zh) * 2008-11-10 2011-10-05 辉瑞股份有限公司 吡咯烷类化合物

Also Published As

Publication number Publication date
JP2012512895A (ja) 2012-06-07
IL213550A0 (en) 2011-07-31
BRPI0922465A2 (pt) 2016-02-10
EP2653193A1 (en) 2013-10-23
UY32346A (es) 2010-07-30
SG196770A1 (en) 2014-02-13
EP2370077A2 (en) 2011-10-05
TW201034675A (en) 2010-10-01
US20110301125A1 (en) 2011-12-08
CA2747478A1 (en) 2010-07-15
MX2011006391A (es) 2011-09-15
AU2009335749A1 (en) 2011-07-07
WO2010080563A3 (en) 2010-08-26
SG172106A1 (en) 2011-07-28
CN102316868A (zh) 2012-01-11
KR20110097955A (ko) 2011-08-31
WO2010080563A2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
AR120109A1 (es) Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
US9765299B2 (en) Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells
EA201490859A1 (ru) Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
PE20190348A1 (es) Moduladores de la via de estres integrada
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
NZ605627A (en) Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase
IN2014DN09221A (es)
ATE496045T1 (de) Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase
AR103283A1 (es) 5-fluoro-4-imino-3-(alquil / alquilo sustituido)-1-(arilsulfonil)-3,4-dihidropirimidin-2(1h)-ona como tratamiento de semillas y plántulas
MX345830B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CU20140023A7 (es) DERIVADOS DE N-(3-(1,2,4-OXADIAZOL-3/5-IL)FENIL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA QUINASA c-Kit
RU2017105781A (ru) Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
AR101177A1 (es) Inhibidores de la syk
PE20141023A1 (es) Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas
CO6630133A2 (es) Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MY163202A (en) Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
NZ599815A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2013016720A3 (en) Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
EA201490545A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ С-Kit
ECSP088913A (es) Derivados de pirimidina tieno [3,2-d] utiles como inhibidores de fi3q

Legal Events

Date Code Title Description
FA Abandonment or withdrawal